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The in vivo biodistribution of liposomal formulations greatly influences the pharmacokinetics of these novel drugs; therefore the
radioisotope labeling of liposomes and the use of nuclear imaging methods for in vivo studies are of great interest. In the present
work, a new procedure for the surface labeling of liposomes is presented using the novel 99mTc-tricarbonyl complex. Liposomes
mimicking the composition of two FDA approved liposomal drugs were used. In the first step of the labeling, thiol-groups were
formed on the surface of the liposomes using Traut’s reagent, which were subsequently used to bind 99mTc-tricarbonyl complex to
the liposomal surface.The labeling efficiency determined by size exclusion chromatography was 95%, and the stability of the labeled
liposomes in bovine serum was found to be 94% over 2 hours. The obtained specific activity was 50MBq per 1 𝜇mol lipid which
falls among the highest values reported for 99mTc labeling of liposomes. Quantitative in vivo SPECT/CT biodistribution studies
revealed distinct differences between the labeled liposomes and the free 99mTc-tricarbonyl, which indicates the in vivo stability of
the labeling. As the studied liposomes were non-PEGylated, fast clearance from the blood vessels and high uptake in the liver and
spleen were observed.
1. Introduction
Liposomes represent one of the first novel drug delivery
systems that are utilized to improve the therapeutic indexes of
various drugs [1, 2]. Liposomes are composed of a phospho-
lipid bilayer, which forms a spherical structure surrounding
an aqueous core [3]. Water-soluble compounds can be incor-
porated into the aqueous compartment of the liposomes,
while nonpolar molecules can be trapped in the hydrocarbon
chain region of the phospholipid bilayer [4]. The versatil-
ity and plasticity of liposomes due to their self-assembled
structure make them clinically useful drug carriers, which
is demonstrated on the high number of approved liposomal
drugs within the nanomedicinal products [5].
Pharmacokinetics and biodistribution of liposomal drugs
and in general all nanomedicines are significantly different
from that of free drugs; thus their characterization is of key
interest [6, 7]. Noninvasive in vivo imaging methods such
as positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) are frequently used
for this purpose [8–13]. Both methods need the labeling
of the liposomal carrier with a radionuclide. Similarly to
the encapsulation of different drugs into the liposomes,
their labeling with radionuclides can be achieved either by
encapsulation into the aqueous interior of the liposomes or by
conjugation to a lipophilic molecule and incorporation into
the phospholipid bilayer.
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The most commonly used medical radioisotope is
technetium-99m (99mTc) due to its easy accessibility through
99Mo/99mTc generator systems and ideal physical properties
such as its half-life (6 hours) and gamma energy (140.5 keV).
Labeling of liposomes with 99mTc was first reported by
surface chelation of the isotope by using stannous chloride
as reducing agent [14, 15]. However, the liposomes labeled
using this technique were found to be unstable in vivo,
similarly to the procedure which utilizes diethylenetriamine-
penta-acetic acid (DTPA) either as encapsulated into the
aqueous core of the liposomes or as conjugated to the surface
of the phospholipid bilayer [16–18]. Entrapment of 99mTc-
hexamethyl-propylene amine oxime (HMPAO) complex by
encapsulating glutathione in the aqueous core of the lipo-
somes was proposed by Phillips et al., which resulted in stable
in vivo labeling for the first time; however the procedure
required a purification step after the labeling because its
efficiency was in the range of 60% to 85% [19]. One of the
most effective labeling instances of liposomeswas achieved by
using a hydrazine nicotinamide (HYNIC)—lipid conjugate
for the surface chelation of 99mTc [20]. The HYNIC labeling
of proteins and peptides as well as liposomes is rapid and
yields stable radioconjugates and, most importantly, it does
not require any postlabeling purification step because its
efficiency is usually above 95% [21].
However, there is a need for the continuous development
of liposome 99mTc-labeling procedures in order to aid quanti-
tative SPECT imaging [22, 23]. One direction in technetium
complex chemistry is the use of novel ligand systems, such
as HYNIC, while the other explores the lower oxidation state
complexes. 99mTc-tricarbonyl core [24] belongs to this group,
in which the oxidation state is +1 in contrast to HYNIC in
which the technetium has an oxidation state of +5 [25, 26].
Therefore 99mTc-tricarbonyl core is chemically inert and has
a compact spherical shape with small size [24, 27]. As a result
of these properties, this complex retains the biological activity
of the labeled object. The 99mTc-tricarbonyl has been used
for the labeling of a wide range of biomolecules from small
tracer molecules to peptides and proteins [28]. Technetium
labeling of liposomes using 99mTc-tricarbonyl complex was
reported previously [8], but the applied procedure can only
be used for liposomes containing a synthetic DTPA-modified
phospholipid.
In the present study, a model liposome system composed
of phosphatidylcholine (PC) and phosphatidylethanolamine
(PE) lipids is chosen to demonstrate the efficiency of the label-
ing with the novel iminothiolane-99mTc-tricarbonyl complex
[29–31]. The studied liposome sample mimics the lipid
composition of two clinically approved liposomal products,
namely, the Epaxal and Inflexal V [32–35]. Liposomal
vaccines such as virosomes and archaeosomes represent a
subgroup within liposomal drug delivery systems. Liposomal
formulations have many advantages over classical vaccines
as discussed in a recent review by Schwendener [36]. The
proposed labeling procedure can be directly used to label such
liposomal formulations, but its application goes beyond that
subgroup. Possibilities concerning the use of the proposed
labeling procedure for the quantitative characterization of the
in vivo biodistribution of other drug delivery systems are also
discussed in this paper.
2. Materials and Methods
2.1. Liposome Preparation and Characterization. Synthetic
highpurity1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)
and1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
were purchased from NOF Corporation (Japan). All chemi-
cals were used without further purification. Unilamellar lipo-
some samples were prepared by the hydration, freeze-thaw,
and extrusion method. Briefly, the components in the weight
ratio of DOPC :DOPE = 4 : 1 were dissolved in chloroform.
The solvent was then evaporated at 40∘C and the resulting
lipid film was kept in vacuum overnight to remove residual
traces of the solvent. 10mM, pH = 7.4 phosphate buffered
saline (PBS, Sigma-Aldrich, Hungary) buffer solution made
of ultrapure water (18.2MΩcm) was added to the samples
to gain a lipid concentration of 10mg/ml. Ten freeze-thaw
cycles by using liquid nitrogen and lukewarm water bath
were applied for homogenization. Finally, the samples were
extruded (at 60∘C) ten times through polycarbonate filters
(Nuclepore, Whatman Inc.) with 100 nm pore size using a
LIPEX extruder (Northern Lipids Inc., Canada).
The size distribution of the liposomes was character-
ized by dynamic light scattering (DLS). DLS measurements
were performed using a W130i apparatus (Avid Nano Ltd.,
High Wycombe, UK) and using a low volume disposable
cuvette (UVette, Eppendorf Austria GmbH). Morphology
of the studied liposomes was investigated by freeze-fracture
transmission electron microscopy (FF-TEM). Fracturing of
2 𝜇L sample was performed at −100∘C in Balzers freeze-
fracture device (Balzers BAF 400D, Balzers AG, Vaduz,
Liechtenstein). The replicas of the fractured faces etched
at −100∘C were made by platinum-carbon shadowing and
then cleaned with a water solution of surfactant and washed
with distilled water. The replicas were placed on 200-mesh
copper grids and examined in a MORGAGNI 268D (FEI,
Netherlands) transmission electron microscope.
2.2. Surface Modification with 2-Iminothiolane and 99mTc-
(CO)
3
Labeling. The surface modification and radiolabeling
of liposomes were performed as shown schematically in
Figure 1. The prepared liposome sample was derivatized
through the primary amine group of DOPE. The free amino
group of DOPE was converted into mercaptobutyrimidyl
group using 2-iminothiolane (2-IT or Traut’s reagent, Sigma-
Aldrich, Hungary) [29–31]. 900 𝜇L of liposome suspension
containing 2.42 𝜇mol of DOPE was mixed with 100 𝜇L stock
solution of 2-IT (14mM solution in PBS) corresponding to
1.4 𝜇mol of 2-IT. The solution was incubated for one hour at
room temperature. The reaction mixture was purified with a
PD-10 desalting column (GE Healthcare Life Sciences) col-
lecting 1mL fraction. The concentration of the thiol-groups
in each fraction was determined by using Ellman’s reagent
(5,5󸀠-dithio-bis-(2-nitrobenzoic acid), DTNB). 50 𝜇L from
each fraction wasmixed with 50 𝜇LDTNB solution (2mM in
50mM sodium-acetate) and with 900 𝜇L Tris buffer (0.1M at
pH = 8). The absorbance values were read at 412 nm using an
Contrast Media & Molecular Imaging 3
Tc
CO
CO
CO
S
HN
PBS, pH 7.4
NH
SH
NH
NH
SH
NH
NH
S
NH
Tc-99m 
NH2
H2O
H2OIsolink
Figure 1: Surface modification of liposomes with 2-Iminothiolane (Traut’s reagent) and labeling with 99mTc-tricarbonyl complex.
UV-Vis spectrophotometer (Hewlett-Packard Agilent 8453),
and a calibration curve was produced using L-cysteine (Alfa
Aesar) solutions ranging from 5 to 30 𝜇M concentration.
The liposome sample with thiol-surface modification
was radiolabeled with 99mTc-tricarbonyl complex
[99mTc(CO)
3
(H
2
O)
3
]+ using a commercial kit (Isolink,
Mallinckrodt Medical B.V.), according to the manufacturer’s
instructions. 0.5–1.5 GBq [99mTcO
4
]− was eluted in 1mL
saline and added to the kit, followed by placing the vial
into boiling water for 20 minutes. The alkaline solution
was neutralized by the addition of approx. 200 𝜇L 1M HCl
solution. 1mL of the surface modified liposome solution was
added to the solution of the 99mTc-tricarbonyl complex and
incubated for one hour at room temperature.
Radiochemical purity was determined by size exclusion
chromatography (SEC) using two different approaches. In
the first set-up, a PD-10 gravity column (GE Healthcare Life
Sciences) was used, in which the chromatography resin is
Sephadex G-25 that is able to separate molecules larger than
5 kDa from small molecules and ions, such as the free Tc-
tricarbonyl complex.The column was eluted with PBS pH 7.4
and 1.5mL fractions were collected and their activities were
subsequentlymeasuredwith aDoseCalibrator ISOMED2010
(MED Nuklear-Medizintechnik Dresden GmbH, Germany)
equipment.
Additionally, SEC measurements were performed with
a Jasco HPLC system (Jasco, Tokyo, Japan) consisting of
a PU-2089 pump with an UV-2075 UV/Vis detector, a
Gamma-RAM radioactive detector (LabLogic Systems Inc.)
and a Rheodyne 7725i injector controlled by the Chromnav
software v. 1.17.02. Tricorn 5/50 high performance column
filledwith SepharoseCL-6B gel (GEHealthcare Life Sciences)
was used for the separation of the radiolabeled liposomes.
The fractionation range of this chromatography resin is from
10 kDa to 4000 kDa for globular proteins, which is not only
applicable to separate the liposomes from small molecular
compounds, but also can be used for the separation of serum
proteins from the liposomes. This column was used for the
quantitative determination of the radiochemical purity of
the labeled liposomes, as well as their in vitro stability in
fetal bovine serum (FCS, Sigma-Aldrich). For the stability
measurements, 100 𝜇L of labeled liposome sample was mixed
with 900 𝜇L of FCS, and 20 𝜇L of the mixture was injected
into the HPLC system at time points of 0, 30, 60, 90, and 120
minutes after mixing. PBS pH 7.4 was used as eluent in all
HPLC investigations.
2.3. In Vivo SPECT/CT Imaging. In vivo imaging was carried
out on BALB/c mice (n = 3, Charles River Hungary). The
body mass of the experimental animals was 28 ± 5 grams and
they were 10–12 weeks old. Animal experiments were carried
out at the Nanobiotechnology & In Vivo Imaging Center
of the Semmelweis University, with permission from the
local institutional animal ethics committee number XIV-I-
001/29-7/2012 and in compliance with the relevant European
Union and Hungarian regulations. Images were acquired
with a NanoSPECT/CT Silver Upgrade (Mediso Ltd., Hun-
gary) sequential animal SPECT/CT imaging system. In the
SPECT/CT experiment 50 ± 10 MBq of 99mTc-labeled lipo-
somes in 200𝜇l volume was injected into the tail vein of
the mice. Control measurements (n = 3) were performed by
injecting 99mTc-tricarbonyl complex only. During the scans
animals were constantly anaesthetized using a mixture of
1–1.5% isoflurane and medical oxygen. The CT and subse-
quent SPECT imaging lasted 10.5 and 30min, respectively.
The body temperature of the animals was maintained at 37∘C
throughout the scanning.
The reconstructed voxel size was 300 𝜇m in 120 × 120
× 328 pixels’ matrix both in SPECT and in CT modalities.
Reconstructed, reoriented, and coregistered images were
further analyzed with Fusion (Mediso Ltd., Hungary) and
VivoQuant (inviCRO LLC, US) dedicated image analysis
software by placing appropriate volume of interests (VOIs)
on the organs.The VOIs were delineatedmanually on each of
the CT scans. Radioactivity concentrations inMBq/cm3 were
determined for each VOI and corrected for scattering and
isotopic decay in the reconstruction algorithm. The uptake
values were measured in the following organs: heart, lungs,
brain, liver, kidneys, spleen, bladder, and vascular system.
The data were evaluated 18, 48, 78, and 108 minutes after the
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500 nm
Figure 2: The morphology of the labeled DOPE/DOPC liposomes
mimicking the commercial virosome formulations as revealed by
FF-TEM.
administration of the control 99mTc-tricarbonyl complex and
43 and 92minutes after the administration of the radiolabeled
liposomes.
3. Results and Discussion
The model liposome system which was used to demon-
strate the proposed new technetium labeling via the novel
iminothiolane-99mTc-tricarbonyl complex mimics the lipid
composition of two clinically approved liposomal formu-
lations, which contains DOPE and DOPC (20 : 80; wt/wt).
Besides those phospholipids the virosomal formulations
also contain hemagglutinin, neuraminidase, and phospho-
lipids from influenza virus. Since the presented labeling
procedure utilizes the primary amino groups of the phos-
phatidylethanolamine, we usedDOPE andDOPC containing
liposomes to model the virosomes. Figure 2 shows the TEM
picture of the freeze-fractured replica of the studied sample.
Fracturing takes place between the two leaflets of the phos-
pholipid bilayer, because the van der Waals forces between
themonolayers are weaker than the hydrogen bonds between
the phospholipid headgroups and the surrounding water.
Therefore, the fractured surface shadowed by the platinum
evaporation from 45 degrees shows the traces of liposomes
broken out from the surface or the traces of liposomes
with one monolayer peeled off during the fracturing. FF-
TEM revealed homogeneous spherical liposomes in the size
range of 100 nm. The average hydrodynamic size of the
liposomes according to the DLS measurement is 110 nm with
a polydispersity index of 0.05 which corresponds to 22.5 nm
standard deviation of the size distribution. In summary,
the FF-TEM and DLS results reveal a monodisperse and
homogeneous liposome system, which mimics the Epaxal
and Inflexal V virosomes regarding their morphology and
lipid composition.
The first step of the labeling is the thiol-surface mod-
ification of the liposomes, which was achieved by the use
of Traut’s reagent as shown in Figure 1. The unsaturated
bond of the reagent reacts with the primary amino group
of the DOPE lipids and forms a free thiol-group via a ring-
opening reaction. The reaction mixture was fractionated
on a PD-10 column and the thiol concentration in each
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Figure 3: The thiol concentration determined by Ellman’s method
of each fraction of the elution of the DOPE/DOPC liposome sample
after surface modification by Traut’s reagent.
fraction was determined by the use of Ellman’s reagent
(Figure 3). The stationary phase of the PD-10 column is
Sephadex G-25, which has a fractionation range of 1–5 kDa;
hence liposomes are excluded from the gel, while small
molecules are eluted at later fractions corresponding to the
total volume of the column. Free thiols react with Ellman’s
reagent in a stoichiometric manner, and the resulting 2-
nitro-5-thiobenzoate dianion gives a yellow color which can
be used for the determination of the thiol concentration
by measuring the absorbance at 412 nm. Figure 3 shows
the thiol concentration of each fraction from the elution
of the reaction mixture on the PD-10 column. Taking into
account the concentration of DOPE lipids in the sample
(2.4 𝜇mol in 1mL), the result presented in Figure 3 indicates
that the first two fractions (at 4 and 5mL elution volumes)
in which the liposome is eluted contain 0.0077𝜇mol thiol-
group, which means that 3.2mol% of the DOPE lipids is
modified. Considering that the DOPE represents 20wt% of
the total lipids, the applied surface modification affects only
the minority of the constituents, which ensure the validity
of the assumption that the biological effect of the labeling is
negligible.
After the surface modification of the liposomes with
Traut’s reagent, the free thiol-groups were used to label
the surface of the liposomes with the 99mTc-tricarbonyl
complex as described in the Materials and Methods. The
crude reaction product was separated using a PD-10 column
and the activity of each fraction was measured separately
(Figure 4). In parallel, the sample was also analyzed by
radio-HPLC-SEC using a Sepharose CL-6B gel (the corre-
sponding chromatogram can be found in the Supplementary
Information, in Supplementary Material available online at
https://doi.org/10.1155/2017/4693417). The labeling efficiency
according to the PD-10 column was found to be in the range
of 90 to 95% which was also confirmed by the radio-HPLC-
SEC measurement. The achieved specific activity—which
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Figure 4: Elution profile of the 99mTc-labeled liposomes on a PD-
10 column. The first two fractions contain the labeled liposomes,
while the free 99mTc-tricarbonyl is eluted with the total volume of
the column.
is a crucial parameter regarding the quantification of the
SPECT imaging results—was 50 to 55MBq per 1 𝜇mol total
phospholipid.
The stability of the labeling in serum was also assessed
by radio-HPLC-SEC using the Sepharose CL-6B gel, which
separates the liposomes from the serum proteins and
small molecules. Only 6% of the total radioactivity became
detached from the liposomes after 2 hours’ incubation in
serum (data shown in the Supplementary Information),
which corresponds to a good in vitro stability.
In vivo SPECT/CT investigations were performed using
the labeled liposomes and with the free 99mTc-tricarbonyl as
control. Appropriate VOIs were used to derive the activity in
the specific organ. Figure 5 shows a typical SPECT/CT image
of the distribution of the labeled liposomes at 92minutes after
administration. High uptake of the labeled liposomes in the
liver, spleen, heart, and vascular system can be observed in
accordance with the reported distribution of non-PEGylated
liposomal systems.
Figure 6 summarizes the distribution of the free 99mTc-
tricarbonyl (Figures 6(a) and 6(c)) and that of the labeled
liposomes within the different organs as a percentage of the
total injected radioactivity and also as standardized uptake
value, known as SUV (Figures 6(b) and 6(d)). SUV is defined
as the ratio of the tissue radioactivity concentration and the
injected activity divided by the body weight (as often used in
PET). It should be noted that the in vivo distribution values
are calculated based on VOIs and include the radioactivity of
the tissue and the blood pool of the organ; therefore it gives an
estimate on the organ uptake. Comparison of the distribution
of the liposomes and that of the free 99mTc-tricarbonyl shows
significant differences. Free 99mTc-tricarbonyl is being gradu-
ally cleared from the circulation during the investigated time
frame, which is reflected in the decreasing radioactivity in the
kidneys and the vascular system and increasing radioactivity
Figure 5: In vivo SPECT/CT images of the 99mTc-labeled liposomes.
The 3D reconstructed and coregistered SPECT and CT image are
shown together with sagittal, coronal, and axial images (from left
to right). Uptake of the liposomes by the liver and spleen is clearly
visible in the images.
in the bladder reaching 24.6 ± 1.96% of the whole-body
radioactivity at 108min p.i. In contrast, the distributions of
the labeled liposomes recorded at the two different time
points show no significant difference. In case of the liposomal
sample, only 1.7 ± 0.82% and 2.8 ± 0.59% of the whole-body
radioactivity are detected in the bladder at 43min and 92min
p.i., respectively, which indicates a good in vivo stability of the
labeling.
The aim of the current manuscript is to introduce
the developed novel liposome labeling procedure, and the
detailed analysis of the obtained distribution is out of the
scope of the paper. However, the comparison of the obtained
results with previous studies on the distribution of liposomes
indicates that the findings reported in this paper show
the expected behavior of non-PEGylated liposomes, that is,
considerable accumulation in the liver and spleen. On the
other hand, the reported in vivo values may be different from
ex vivo values in the heart, liver, and kidneys, because of the
contribution from the blood pool of these organs.
It is worth pointing out that most of the studies deal
with the biodistribution of PEGylated liposomes, and, to
the best of our knowledge, the radiolabeling and in vivo
nuclear imaging study of liposomes mimicking the lipid
composition of Epaxal and Inflexal V has not yet been
reported in the literature. The proposed labeling procedure
utilizes the primary amino group of the PE lipids, which
is the constituent of the used liposomal formulation, but
most of the formulations contain only PC lipids, PEG-lipids,
and cholesterol. However, conventional liposomal formula-
tion can also be labeled with the proposed method after
insertion of PE lipids, amine-functionalized PEG-lipids, or
lipid derivatives with thiol-groups via the micellar fusion or
the detergent dialysis methods used for the reconstitution of
amphiphilic compounds into preformed liposomes [37, 38].
In a wider sense, the introduced method can be utilized to
any drug delivery system with amino groups on their surface
and results in a stable labeling with high specific activity.
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Figure 6: In vivo distribution of the free 99mTc-tricarbonyl complex (a and c) and that of the 99mTc-labeled liposomes (b and d) represented in
the percentage of the whole-body radioactivity and as the standardized uptake values (SUVs) for the specified organs. Values were calculated
based on the volume of interests (VOIs) corresponding to the different organs and include the radioactivity of the tissue and the blood pool
of the organ.
4. Conclusions
A novel procedure is presented in this paper for the surface
labeling of liposomes with 99mTc by using the iminothiolane-
99mTc-tricarbonyl complex. The proposed method utilizes
the primary amino groups of the PE lipids and uses Traut’s
reagent for the formation of thiol-groups on the liposomal
surface. The surface modification was verified using Ellman’s
test, which revealed that only the minority of the PE lipids
is modified, which ensures that the labeling does not alter
significantly the in vivo behavior of the liposomes. The
specific activity achievable for the 99mTc labeling of liposomes
with the presented method is among the highest reported in
the literature, which enables the quantitative SPECT imaging.
The small size and low oxidation state of 99mTc in the
complex ensure the good in vitro and in vivo stability of
the labeling. The presented method is applicable to other
liposomal formulations as well after the post insertion of
PE lipids into the liposomes but also to other drug delivery
systems, which either contain primary amino groups (such
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as poly(amidoamine) dendrimers) or can be aminated (such
as silica nanoparticles).
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